The EXAMINE and SAVOR-TIMI 53 studies were excluded from sensitivity analyses because DPP-IV inhibitor drugs did not show CV benefit in their individual trials
What remains most novel about GLP-1 medications is that they target underlying biological drivers of energy intake and metabolic regulationfactors closely tied to chronic disease riskrather than simply promoting short-term weight reduction, and may, in the long run, contribute to lower health insurance costs by treating related comorbidities, even as they may impact patient longevity and, thus, how life insurance treats these drugs
Source of reviews and verification methodology not disclosed in publicly available documentation
Tissue Histology for Morphology, Lipid Content and Fibrosis Heart and liver tissue samples were collected at the time of sacrifice and fixed in a 10% zinc formalin buffered solution (CUNZF-5-G, Azer Scientific, Morgantown, PA, USA) for 48 hours, followed by transfer to a storage solution of 0.01% sodium azide in PBS
We also stay in touch with you throughout your weight loss journey
Novo Nordisk is also continuing to run additional studies, including testing higher doses, to better understand the treatments full potential